US4849334A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Human papillomavirus 43 nucleic acid hybridization probes and methods for employing the same
Assignee: Qiagen Gaithersburg LLC
•
Filing: 1987-06-09
•
Granted: 1989-07-18
•
Expires: 2007-06-09
Abstract
Abstract Nucleic acid hybridization probes for human papillomavirus types and particularly human papillomavirus type 43; and methods for employing the same.
Inventors
- 👤 Attila T. Lorincz
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-29 08:13
CPC Classifications
C; C12; C12Q; C12Q1/00; C12Q1/70; C12Q1/701; C12Q1/708; Y; Y10; Y10S; Y10S435/00; Y10S435/8215; Y10S435/948
Claims Analysis
Total Claims: 102
Claim 1
Independent Claim
20 words
A recombinant DNA of HPV 43 comprising a cloning vector and substantially all of HPV 43 DNA or fragments thereof.
Claim 2
Dependent Claim
20 words
A recombinant DNA of HPV 43 comprising a cloning vector and substantially all of HPV 43 DNA or fragments thereof.
Claim 3
Dependent Claim
38 words
The recombinant DNA of HPV 43 as claimed in claim 1, wherein said cloning vector is selected from the group consisting of pBR322, pUC11, λ charon, λ L47, M13 derived bacteriophage, pZIP-Neo SV [X1], pBKTK-1, pT712 and pT713.
Claim 4
Dependent Claim
24 words
The recombinant DNA of HPV 43 as claimed in claim 1, wherein said fragments are about 15 to about 8000 base pairs in size.
Claim 5
Dependent Claim
24 words
The recombinant DNA of HPV 43 as claimed in claim 3, wherein said fragments are about 300 to about 800 base pairs in size.
Claim 6
Dependent Claim
34 words
The recombinant DNA of HPV 43 as claimed in claim 1, wherein said recombinant DNA has the identifying characteristics of HPV 43 clones 2A and 2B (ATCC No. 40338 and ATCC No. 40339, respectively).
Claim 7
Dependent Claim
24 words
The recombinant DNA of HPV 43 as claimed in claim 1, wherein the HPV DNA of said recombinant DNA is labelled with a marker.
Claim 8
Dependent Claim
18 words
The recombinant DNA of HPV 43 as claimed in claim 6, wherein said marker is a radioactive marker.
Claim 9
Dependent Claim
35 words
The recombinant DNA of HPV 43 as claimed in claim 7, wherein said marker is a radioactive marker selected from the group consisting of 32 P, 14 C, 3 H, 125 I and 35 S.
Claim 10
Dependent Claim
31 words
The recombinant DNA of HPV 43 as claimed in claim 6, wherein said marker is a non-radiactive marker selected from the group consisting of biotin, an enzyme and a fluorescent molecule.
Claim 11
Dependent Claim
26 words
The recombinant DNA of HPV 43 as claimed in claim 9, wherein said enzyme is selected from the group consisting of alkaline phosphatase and horseradish peroxidase.
Claim 12
Dependent Claim
25 words
The recombinant DNA of HPV 43 as claimed in claim 9, wherein said fluorescent molecule is selected from the group consisting of fluorescein and rhodamine.
Claim 13
Dependent Claim
8 words
Essentially pure HPV 43 DNA or fragments thereof.
Claim 14
Dependent Claim
8 words
Essentially pure HPV 43 DNA or fragments thereof.
Claim 15
Dependent Claim
22 words
The essentially pure HPV 43 DNA as claimed in claim 12, wherein said HPV 43 DNA or fragments thereof are produced biologically.
Claim 16
Dependent Claim
22 words
The essentially pure HPV 43 DNA as claimed in claim 12, wherein said HPV 43 DNA or fragments thereof are produced chemically.
Claim 17
Dependent Claim
26 words
The essentially pure HPV 43 DNA as claimed in claim 12, wherein said fragments are about 15 to about 8000 bases or base pairs in size.
Claim 18
Dependent Claim
26 words
The essentially pure HPV 43 DNA as claimed in claim 15, wherein said fragments are about 300 to about 800 bases or base pairs in size.
Claim 19
Dependent Claim
24 words
The essentially pure HPV 43 DNA as claimed in claim 12, wherein said HPV 43 DNA or fragments thereof are labelled with a marker.
Claim 20
Dependent Claim
18 words
The essentially pure HPV 43 DNA as claimed in claim 17, wherein said marker is a radioactive marker.
Claim 21
Dependent Claim
35 words
The essentially pure HPV 43 DNA as claimed in claim 18, wherein said marker is a radioactive marker selected from the group consisting of 32 P, 14 C, 3 H, 125 I and 35 S.
Claim 22
Dependent Claim
31 words
The essentially pure HPV 43 DNA as claimed in claim 17, wherein said marker is a non-radiactive marker selected from the group consisting of biotin, an enzyme and a fluorescent molecule.
Claim 23
Dependent Claim
26 words
The essentially pure HPV 43 DNA as claimed in claim 20, wherein said enzyme is selected from the group consisting of alkaline phosphatase and horseradish peroxidase.
Claim 24
Dependent Claim
25 words
The essentially pure HPV 43 DNA as claimed in claim 20, wherein said fluorescent molecule is selected from the group consisting of fluorescein and rhodamine.
Claim 25
Dependent Claim
8 words
Essentially pure HPV 43 RNA or fragments thereof.
Claim 26
Dependent Claim
8 words
Essentially pure HPV 43 RNA or fragments thereof.
Claim 27
Dependent Claim
22 words
The essentially pure HPV 43 RNA as claimed in claim 23, wherein said HPV 43 RNA or fragments thereof are produced biologically.
Claim 28
Dependent Claim
22 words
The essentially pure HPV 43 RNA as claimed in claim 23, wherein said HPV 43 RNA or fragments thereof are produced chemically.
Claim 29
Dependent Claim
26 words
The essentially pure HPV 43 RNA as claimed in claim 23, wherein said fragments are about 15 to about 8000 bases or base pairs in size.
Claim 30
Dependent Claim
26 words
The essentially pure HPV 43 RNA as claimed in claim 26, wherein said fragments are about 300 to about 800 bases or base pairs in size.
Claim 31
Dependent Claim
24 words
The essentially pure HPV 43 RNA as claimed in claim 23, wherein said HPV 43 RNA or fragments thereof are labelled with a marker.
Claim 32
Dependent Claim
18 words
The essentially pure HPV 43 RNA as claimed in claim 28, wherein said marker is a radioactive marker.
Claim 33
Dependent Claim
35 words
The essentially pure HPV 43 RNA as claimed in claim 29, wherein said marker is a radioactive marker selected from the group consisting of 32 P, 14 C, 3 H, 125 I and 35 S.
Claim 34
Dependent Claim
31 words
The essentially pure HPV 43 RNA as claimed in claim 28, wherein said marker is a non-radiactive marker selected from the group consisting of biotin, an enzyme and a fluorescent molecule.
Claim 35
Dependent Claim
26 words
The essentially pure HPV 43 RNA as claimed in claim 31, wherein said enzyme is selected from the group consisting of alkaline phosphatase and horseradish peroxidase.
Claim 36
Dependent Claim
25 words
The essentially pure HPV 43 RNA as claimed in claim 31, wherein said fluorescent molecule is selected from the group consisting of fluorescein and rhodamine.
Claim 37
Dependent Claim
37 words
An HPV 43 hybridization probe comprising a member selected from the group consisting of (i) HPV 43 DNA or fragments thereof labelled with a marker and (ii) HPV 43 RNA or fragments thereof labelled with a marker.
Claim 38
Dependent Claim
37 words
An HPV 43 hybridization probe comprising a member selected from the group consisting of (i) HPV 43 DNA or fragments thereof labelled with a marker and (ii) HPV 43 RNA or fragments thereof labelled with a marker.
Claim 39
Dependent Claim
25 words
The HPV 43 hybridization probe as claimed in claim 34, wherein said fragments are about 15 to about 8000 bases or base pairs in size.
Claim 40
Dependent Claim
25 words
The HPV 43 hybridization probe as claimed in claim 35, wherein said fragments are about 300 to about 800 bases or base pairs in size.
Claim 41
Dependent Claim
17 words
The HPV 43 hybridization probe as claimed in claim 34, wherein said marker is a radioactive marker.
Claim 42
Dependent Claim
34 words
The HPV 43 hybridization probe as claimed in claim 37, wherein said marker is a radioactive marker selected from the group consisting of 32 P, 14 C, 3 H, 125 I and 35 S.
Claim 43
Dependent Claim
30 words
The HPV 43 hybridization probe as claimed in claim 34, wherein said marker is a non-radioactive marker selected from the group consisting of biotin, an enzyme and a fluorescent molecule.
Claim 44
Dependent Claim
25 words
The HPV 43 hybridization probe as claimed in claim 39, wherein said enzyme is selected from the group consisting of alkaline phosphatase and horseradish peroxidase.
Claim 45
Dependent Claim
24 words
The HPV 43 hybridization probe as claimed in claim 39, wherein said fluorescent modecule is selected from the group consisting of fluorescein and rhodamine.
Claim 46
Dependent Claim
57 words
An HPV hybridization probe composition comprising (a) a member selected from the group consisting of (i) HPV 43 DNA or fragments thereof labelled with a marker and (ii) HPV 43 RNA or fragments thereof labelled with a marker and (b) DNA or RNA or fragments thereof of at least one other HPV type labelled with a marker.
Claim 47
Dependent Claim
57 words
An HPV hybridization probe composition comprising (a) a member selected from the group consisting of (i) HPV 43 DNA or fragments thereof labelled with a marker and (ii) HPV 43 RNA or fragments thereof labelled with a marker and (b) DNA or RNA or fragments thereof of at least one other HPV type labelled with a marker.
Claim 48
Dependent Claim
30 words
The HPV hybridization probe composition as claimed in claim 42, wherein at least any one of said fragments are about 15 to about 8000 bases or base pairs in size.
Claim 49
Dependent Claim
30 words
The HPV hybridization probe composition as claimed in claim 43, wherein at least ony one of said fragments are about 300 to about 800 bases or base pairs in size.
Claim 50
Dependent Claim
22 words
The HPV hybridization probe composition as claimed in claim 42, wherein at least any one of said marker is a radioactive marker.
Claim 51
Dependent Claim
39 words
The HPV hybridization probe composition as claimed in claim 45, wherein at least any one of said marker is a radioactive marker selected from the group consisting of 32 P, 14 C, 3 H, 125 I and 35 S.
Claim 52
Dependent Claim
35 words
The HPV hybridization probe composition as claimed in claim 42, wherein at least any one of said marker is a non-radioactive marker selected from the group consisting of biotin, an enzyme and a fluorescent molecule.
Claim 53
Dependent Claim
25 words
The HPV hybridization probe composition as claimed in claim 47, wherein said enzyme is selected from the group consisting of alkaline phosphatase and horseradish peroxidase.
Claim 54
Dependent Claim
24 words
The HPV hybridization probe composition as claimed in claim 47, wherein said fluorescent molecule is selected from the group consisting of fluorescein and rhodamine.
Claim 55
Dependent Claim
37 words
The HPV hybridization probe composition as claimed in claim 42, wherein said other HPV type is at least one member selected from the group consisting of HPV 6, HPV 11, HPV 16, HPV 18 and HPV 31.
Claim 56
Dependent Claim
33 words
The HPV hybridization probe composition as claimed in claim 50, wherein said other HPV type is at least one member selected from the group consisting of HPV 16, HPV 18 and HPV 31.
Claim 57
Dependent Claim
23 words
The HPV hybridization probe composition as claimed in claim 51, wherein said other HPV type is HPV 16, HPV 18 and HPV 31.
Claim 58
Independent Claim
98 words
A method for detecting HPV DNA or RNA comprising: (1) carrying out hybridization, under non-stringent conditions with (a) a labelled HPV 43 nucleic acid selected from the group consisting of (i) HPV 43 DNA or fragments thereof labelled with a marker, and (ii) HPV 43 RNA or fragments thereof labelled with a marker; (b) an unknown sample of DNA or RNA, and (c) at least one other labelled HPV-type nucleic acid; and (2) assaying for the presence of cross-hybridization between all labelled nucleic acid and unknown sample so as to detect HPV DNA or RNA in said sample.
Claim 59
Independent Claim
98 words
A method for detecting HPV DNA or RNA comprising: (1) carrying out hybridization, under non-stringent conditions with (a) a labelled HPV 43 nucleic acid selected from the group consisting of (i) HPV 43 DNA or fragments thereof labelled with a marker, and (ii) HPV 43 RNA or fragments thereof labelled with a marker; (b) an unknown sample of DNA or RNA, and (c) at least one other labelled HPV-type nucleic acid; and (2) assaying for the presence of cross-hybridization between all labelled nucleic acid and unknown sample so as to detect HPV DNA or RNA in said sample.
Claim 60
Dependent Claim
25 words
The method as claimed in claim 53, wherein said unknown sample of DNA or RNA is derived from a genital, throat, oral or skin lesion.
Claim 61
Dependent Claim
21 words
The method as claimed in claim 54, wherein said unknown sample of DNA or RNA is derived from a genital lesion.
Claim 62
Dependent Claim
55 words
The method as claimed in claim 55, wherein said unknown sample of DNA or RNA derived from a genital lesion is obtained by biopsying an epithelial lesion, scraping the cervix or by swabbing the cervix to obtain exfoliated cells or is DNA derived from a genital lesion which has been closed in a cloning vector.
Claim 63
Dependent Claim
27 words
The method as claimed in claim 53, wherein at least any one of said fragments are about 15 to about 8000 bases or base pairs in size.
Claim 64
Dependent Claim
27 words
The method as claimed in claim 57, wherein at least any one of said fragments are about 300 to about 800 bases or base pairs in size.
Claim 65
Dependent Claim
112 words
The method as claimed in claim 53, (c) said at least one other labelled HPV-type nucleic is selected from the group consisting of: (i) HPV 6 DNA or fragments thereof labelled with a marker; (ii) HPV 6 RNA or fragments thereof labelled with a marker; (iii) HPV 11 DNA or fragments thereof labelled with a marker; (iv) HPV 11 RNA or fragments thereof labelled with a marker; (v) HPV 16 DNA or fragments thereof labelled with a marker; (vi) HPV 16 RNA or fragments thereof labelled with a marker; (vii) HPV 18 DNA or fragments thereof labelled with a marker; and (viii) HPV 18 RNA or fragments thereof labelled with a marker.
Claim 66
Dependent Claim
28 words
The method as claimed in claim 59, wherein said other HPV type is at least one member selected from the group consisting of HPV 16 and HPV 18.
Claim 67
Dependent Claim
18 words
The method as claimed in claim 60, wherein said other HPV type is HPV 16 and HPV 18.
Claim 68
Dependent Claim
19 words
The method as claimed in claim 53, wherein at least any one of said marker is a radioactive marker.
Claim 69
Dependent Claim
36 words
The method as claimed in claim 62, wherein at least any one of said marker is a radioactive marker selected from the group consisting of 32 P, 14 C, 3 H, 125 I and 35 S.
Claim 70
Dependent Claim
32 words
The method as claimed in claim 53, wherein at least any one of said marker is a non-radiactive marker selected from the group consisting of biotin, an enzyme and a fluorescent molecule.
Claim 71
Dependent Claim
22 words
The method as claimed in claim 64, wherein said enzyme is selected from the group consisting of alkaline phosphatase and horseradish peroxidase.
Claim 72
Dependent Claim
21 words
The method as claimed in claim 64, wherein said fluorescent molecule is selected from the group consisting of fluorescein and rhodamine.
Claim 73
Dependent Claim
13 words
The method as claimed in claim 53, wherein said cross-hybridization produces DNA-DNA hybrids.
Claim 74
Dependent Claim
13 words
The method as claimed in claim 53, wherein said cross-hybridization produces DNA-RNA hybrids.
Claim 75
Independent Claim
78 words
A method for detecting HPV 43 DNA or RNA comprising: (1) carrying out hybridization, under stringent conditions, with (a) a member selected from the group consisting of (i) HPV 43 DNA or fragments thereof labelled with a marker, and (ii) HPV 43 RNA or fragments thereof labelled with a marker; (b) an unknown sample of DNA or RNA, and (2) assaying for the presence of cross-hybridization so as to detect HPV 43 DNA or RNA in said sample.
Claim 76
Independent Claim
78 words
A method for detecting HPV 43 DNA or RNA comprising: (1) carrying out hybridization, under stringent conditions, with (a) a member selected from the group consisting of (i) HPV 43 DNA or fragments thereof labelled with a marker, and (ii) HPV 43 RNA or fragments thereof labelled with a marker; (b) an unknown sample of DNA or RNA, and (2) assaying for the presence of cross-hybridization so as to detect HPV 43 DNA or RNA in said sample.
Claim 77
Dependent Claim
25 words
The method as claimed in claim 69, wherein said unknown sample of DNA or RNA is derived from a genital, throat, oral or skin lesion.
Claim 78
Dependent Claim
21 words
The method as claimed in claim 70, wherein said unknown sample of DNA or RNA is derived from a genital lesion.
Claim 79
Dependent Claim
55 words
The method as claimed in claim 71, wherein said unknown sample of DNA or RNA derived from a genital lesion is obtained by biopsying an epithelial lesion, scraping the cervix or by swabbing the cervix to obtain exfoliated cells or is DNA derived from a genital lesion which has been cloned in a cloning vector.
Claim 80
Dependent Claim
22 words
The method as claimed in claim 69, wherein said fragments are about 15 to about 8000 bases or base pairs in size.
Claim 81
Dependent Claim
22 words
The method as claimed in claim 73, wherein said fragments are about 300 to about 800 bases or base pairs in size.
Claim 82
Dependent Claim
20 words
The method as claimed in claim 69, wherein said HPV 43 DNA comprises substantially all of the HPV 43 genome.
Claim 83
Dependent Claim
14 words
The method as claimed in claim 69, wherein said marker is a radioactive marker.
Claim 84
Dependent Claim
31 words
The method as claimed in claim 76, wherein said marker is a radioactive marker selected from the group consisting of 32 P, 14 C, 3 H, 125 I and 35 S.
Claim 85
Dependent Claim
27 words
The method as claimed in claim 69, wherein said marker is a non-radioactive marker selected from the group consisting of biotin, an enzyme and a fluorescent molecule.
Claim 86
Dependent Claim
22 words
The method as claimed in claim 78, wherein said enzyme is selected from the group consisting of alkaline phosphatase and horseradish peroxidase.
Claim 87
Dependent Claim
21 words
The method as claimed in claim 78, wherein said fluorescent molecule is selected from the group consisting of fluorescein and rhodamine.
Claim 88
Dependent Claim
13 words
The method as claimed in claim 69, wherein said cross-hybridization produces DNA-DNA hybrids.
Claim 89
Dependent Claim
13 words
The method as claimed in claim 69, wherein said cross-hybridization produces DNA-RNA hybrids.
Claim 90
Independent Claim
278 words
A method for detecting HPV 43 DNA or RNA comprising: (1) carrying out hybridization, under stringent conditions, with (a) a first fraction of DNA or RNA derived from each individual genital lesion of a sampling of genital lesions, which sampling shows an epidemiological progression to cervical cancer, and (b) a member selected from the group consisting of (i) HPV 43 DNA or fragments thereof labelled with a marker, and (ii) HPV 43 RNA or fragments thereof labelled with a marker; and assaying for the presence of cross-hybridization with the DNA or RNA derived from each individual genital lesion of said sampling of genital lesions; (2) carrying out hybridization, under stringent conditions, with (a) a second fraction of DNA or RNA derived from each individual genital lesion of said sampling of genital lesions, and (b) an unknown sample of DNA or RNA derived from a genital lesion which has been labelled with a marker; and assaying for the presence of cross-hybridization with the DNA or RNA derived from each individual genital lesion of said sampling of genital lesions; (3) comparing the overall patterns of cross-hybridization of said sampling of genital lesions obtained in Step (1) with that obtained in Step (2); and (4) comparing the cross-hybridizations of each individual genital lesion of said sampling of genital lesions obtained in Step (1) with that obtained in Step (2); wherein the presence of HPV 43 DNA or RNA in said unknown sample is detected when both (i) the overall patterns of cross-hybridization of said sampling of genital lesions are essentially the same, and (ii) the cross-hybridizations of each individual genital lesion of said sampling of genital lesions are essentially the same.
Claim 91
Independent Claim
278 words
A method for detecting HPV 43 DNA or RNA comprising: (1) carrying out hybridization, under stringent conditions, with (a) a first fraction of DNA or RNA derived from each individual genital lesion of a sampling of genital lesions, which sampling shows an epidemiological progression to cervical cancer, and (b) a member selected from the group consisting of (i) HPV 43 DNA or fragments thereof labelled with a marker, and (ii) HPV 43 RNA or fragments thereof labelled with a marker; and assaying for the presence of cross-hybridization with the DNA or RNA derived from each individual genital lesion of said sampling of genital lesions; (2) carrying out hybridization, under stringent conditions, with (a) a second fraction of DNA or RNA derived from each individual genital lesion of said sampling of genital lesions, and (b) an unknown sample of DNA or RNA derived from a genital lesion which has been labelled with a marker; and assaying for the presence of cross-hybridization with the DNA or RNA derived from each individual genital lesion of said sampling of genital lesions; (3) comparing the overall patterns of cross-hybridization of said sampling of genital lesions obtained in Step (1) with that obtained in Step (2); and (4) comparing the cross-hybridizations of each individual genital lesion of said sampling of genital lesions obtained in Step (1) with that obtained in Step (2); wherein the presence of HPV 43 DNA or RNA in said unknown sample is detected when both (i) the overall patterns of cross-hybridization of said sampling of genital lesions are essentially the same, and (ii) the cross-hybridizations of each individual genital lesion of said sampling of genital lesions are essentially the same.
Claim 92
Dependent Claim
22 words
The method as claimed in claim 83, wherein said fragments are about 15 to about 8000 bases or base pairs in size.
Claim 93
Dependent Claim
22 words
The method as claimed in claim 84, wherein said fragments are about 300 to about 800 bases or base pairs in size.
Claim 94
Dependent Claim
20 words
The method as claimed in claim 83, wherein said HPV 43 DNA comprises substantially all of the HPV 43 genome.
Claim 95
Dependent Claim
19 words
The method as claimed in claim 83, wherein at least any one of said marker is a radioactive marker.
Claim 96
Dependent Claim
36 words
The method as claimed in claim 87, wherein at least any one of said marker is a radioactive marker selected from the group consisting of 32 P, 14 C, 3 H, 125 I and 35 S.
Claim 97
Dependent Claim
32 words
The method as claimed in claim 83, wherein at least any one of said marker is a non-radioactive marker selected from the group consisting of biotin, an enzyme and a fluorescent molecule.
Claim 98
Dependent Claim
22 words
The method as claimed in claim 89, wherein said enzyme is selected from the group consisting of alkaline phosphatase and horseradish peroxidase.
Claim 99
Dependent Claim
21 words
The method as claimed in claim 89, wherein said fluorescent molecule is selected from the group consisting of fluorescein and rhodamine.
Claim 100
Dependent Claim
55 words
The method as claimed in claim 83, wherein said unknown sample of DNA or RNA derived from a genital lesion is obtained by biopsying an epithelial lesion, scraping the cervix or by swabbing the cervix to obtain exfoliated cells or is DNA derived from a genital lesion which has been cloned in a cloning vector.
Claim 101
Dependent Claim
18 words
The method as claimed in claim 83, wherein at least any one of said cross-hybridization produces DNA-DNA hybrids.
Claim 102
Dependent Claim
18 words
The method as claimed in claim 83, wherein at least any one of said cross-hybridization produces DNA-RNA hybrids.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-07-17 | 1993-01-16 | 1993-07-18 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-07-17 | 1997-01-16 | 1997-07-18 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-07-17 | 2001-01-16 | 2001-07-18 | $7700.00 | Window Closed / Lapsed |